HMG-CoA Reductase Inhibitors in Chronic Heart Failure

@article{Laufs2006HMGCoARI,
  title={HMG-CoA Reductase Inhibitors in Chronic Heart Failure},
  author={Ulrich Laufs and Florian Custodis and Michael Prof. Dr. B{\"o}hm},
  journal={Drugs},
  year={2006},
  volume={66},
  pages={145-154}
}
HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure were generally excluded in the existing trials and a different patient population with a distinct pattern of morbidity and treatment was studied. In addition, no safety data are… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 84 REFERENCES

Pleiotropic effects of statins.

VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Beyond lipid-lowering: effects of statins on endothelial nitric oxide

  • Ulrich Laufs
  • Medicine
  • European Journal of Clinical Pharmacology
  • 2003
VIEW 2 EXCERPTS

Increased oxidative stress in patients with congestive heart failure.

VIEW 1 EXCERPT

Impact of HMG CoA reductase inhibition on small GTPases in the heart.

VIEW 6 EXCERPTS